Daniel Marshall, DO
MOHS-Micrographic Surgery · Rexburg, IDNPI 1861583486
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 25.3% of the total.
Across 97 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$454
- Lilly USA, LLC$369
- Novartis$167
- UCB, Inc.$126
- Biofrontera Inc.$91
- Dermavant Sciences, Inc.$86
- plus $500 from 15 others
What the payments were for
- Food & beverage$1,793100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $454 |
| Lilly USA, LLC | 17 | $369 |
| Novartis | 9 | $167 |
| UCB, Inc. | 6 | $126 |
| Biofrontera Inc. | 6 | $91 |
| Dermavant Sciences, Inc. | 4 | $86 |
| Neurocrine Biosciences, Inc. | 3 | $67 |
| Amgen | 3 | $58 |
| Galderma Laboratories, L.p. | 2 | $55 |
| Johnson & Johnson | 4 | $55 |
| Sun Pharmaceutical Industries Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Bioxcel Therapeutics, Inc. | 1 | $31 |
| Merck | 2 | $28 |
| Incyte Corporation | 2 | $28 |
| Pfizer | 2 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Sanofi | 1 | $25 |
| Dermira, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Organon | 1 | $8 |
How this compares
Too few mohs-micrographic surgery providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metronidazole | 67 | $4,224 |
| Clobetasol Propionate | 113 | $3,859 |
| Fluorouracil | 31 | $3,255 |
| Ketoconazole | 213 | $3,157 |
| Fluocinonide | 30 | $2,024 |
| Imiquimod | 42 | $1,929 |
| Doxycycline Hyclate | 36 | $1,430 |
| Fluconazole | 23 | $1,419 |
| ValacyclovirValacyclovir Hcl | 34 | $1,019 |
| Mupirocin | 137 | $947 |
| Triamcinolone Acetonide | 69 | $754 |
| Minocycline Hcl | 17 | $726 |
| Cephalexin | 129 | $654 |
| Minoxidil | 96 | $647 |
| MethotrexateMethotrexate Sodium | 32 | $435 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Rexburg
- Brandon MinerIdaho Falls$5K
- Daniel WinchesterMeridian$4K
- Ryan ThorpeMeridian$4K
- Earl StoddardChubbuck$3K
- Peter BoothmanMeridian$2K
- David GriffinTwin Falls$789
- Teri CottinghamBoise$149
- Kurtis ReedTwin Falls$32
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.